Fierce Drug Dev Forum 2019 has ended
avatar for Albert Hsia 

Albert Hsia 

Bussiness Development 
Albert Hsia focuses on partnership and M&A opportunities for Merck in immuno-oncology and immunology, as well as in new therapeutic modalities and platforms with potential across disease areas.  Merck builds strong partnerships with innovative biotechs globally, based on early-stage science to clinical-stage programs, to invent and bring forward medicines for the most challenging diseases.  Albert has led and co-led the successful completion of a wide range of Merck’s significant recent transactions.  

Albert came to Merck with over 15 years of experience in biotech, from company formation to exit and from early discovery to late clinical development. Prior to Merck, Albert was most recently an entrepreneur-in-residence at Atlas Venture and the Chief Business Officer of Disarm Therapeutics. He holds a Ph.D. in neuroscience from U.C. San Francisco and a B.A. in chemistry and physics from Harvard University.

My Speakers Sessions

Monday, October 28

1:15pm PDT